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index and mitral E/e′ (p < 0.01). In the HCM-risk group, 
myostatin was decreased (p = 0.004), whereas ICAM was 
increased (p = 0.002). Global perfusion was decreased in 
the HCM group (p < 0.05) versus controls. Endostatin and 
mitral E/e′ correlated inversely to myocardial perfusion 
(p ≤ 0.05). This is the first study demonstrating adverse 
changes in biomarkers reflecting myocardial matrix remod-
eling, microfibrosis, and vascular endotheliopathy in early 
stage of hypertrophic cardiomyopathy in the young.
Keywords Hypertrophic cardiomyopathy · Risk · Early 
stage · Biomarkers · Myocardium
Introduction
Hypertrophic cardiomyopathy (HCM) is the most com-
mon monogenic cardiac disorder and is one of the leading 
causes of sudden cardiac death in the young. HCM is char-
acterized by gradual thickening of the cardiac muscle and 
increased risk for major cardiac events, including ventric-
ular arrhythmias and sudden cardiac death [1–3]. As sar-
comere gene mutations can be found in nearly two-thirds 
of HCM cases [2, 4–6], genetic testing is recommended to 
identify presymptomatic relatives at risk [2, 4].
The complexity of the disease includes intracellular as 
well as extracellular changes [7–9].
Postmortem studies of HCM heart specimens have 
demonstrated myocyte disarray, fibrosis, and remodeling, 
as well as changes in the coronary circulation, particu-
larly at the microvascular level [7–9]. There is also evi-
dence of increased myocardial extracellular volume in 
individuals with HCM-causing mutations in the absence 
of overt hypertrophy [10]. We have recently demonstrated 
changes in the cardiac diastolic function and peripheral 
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microvascular function in children and young adults with 
HCM or at risk for this disease [11]. There are limited data 
regarding the myocardial remodeling process and the time-
line of these changes in the early phase of HCM.
Whether these important morphological features can be 
tracked in the blood of young individuals with HCM has 
not been yet reported. Cardiac extracellular matrix (ECM) 
is predominantly composed of type I (85%) and type III 
(11%) collagen synthesized by cardiac fibroblasts, and 
plays an important role in myocardial remodeling [12]. The 
C-terminal telopeptide of collagen type I (ICTP) can be 
used as a marker of collagen degradation [13]. ICTP under-
goes spontaneous denaturation into inactive fragments. 
Matrix metalloproteinases (MMP) 2 and 9 are part of the 
enzyme system primarily responsible for ECM degradation 
and turnover [12]. Elevated serum levels of MMP-2 and 
MMP-9 have been observed in adult HCM patients [14]. 
Recently, elevated serum levels of C-terminal telopeptide 
of collagen type I (ICTP) have been found in adult patients 
with DCM and HCM [13–16] and also in presymptomatic 
adults at risk for developing HCM [17]. Cathepsin S is one 
of the major cysteine proteases, being expressed in the lys-
osome of the antigen-presenting cells [18]. Cathepsin S is 
also an important regulator of endostatin [19], which is the 
C-terminal fragment of collagen XVIII found in the base-
ment membrane zones around blood vessels. Endostatin 
acts as an antiangiogenic growth factor and is suggested to 
be synthetized in the coronary circulation in patients with 
coronary heart disease. It may play an important role in 
the regulation of coronary angiogenesis [20–22], which is 
markedly impaired in advanced stages of HCM. Endosta-
tin has also been suggested to be a marker for extracellular 
matrix remodeling in the heart [23]. Myostatin is a pro-
tein derived from the transforming growth factor (TGF)-
family, and exerts inhibiting effect on the skeletal muscle 
cell growth and myogenic differentiation [24]. Myosta-
tin is mainly found not only in skeletal muscle but also in 
the heart and adipose tissue. Myostatin can be induced in 
response to cardiac stress, mechanical stretch, or humoral 
factors such as IGF-1, phenylephrine, or angiotensin II, 
and has both profibrotic and antihypertrophic actions [24]. 
Gross muscle hypertrophy has been demonstrated in a pedi-
atric case presenting with loss of function in the myostatin 
gene [25]. In this case, there was a very low level of cir-
culating myostatin, whereas increased levels of myostatin 
have been reported in patients with severe heart failure due 
to ischemic and dilated cardiomyopathy [26] and elevated 
levels of myostatin are thought to contribute to cardiac 
cachexia [24].
Intercellular adhesion molecule (ICAM) and vascu-
lar cell adhesion molecule (VCAM) are central in the 
transendothelial migration of inflammatory cells, with 
a role in endothelial signaling and adhesion as part of 
the proinflammatory response [27]. Vascular endothelial 
growth factor receptor 1 (VEGFR1) has long been used as a 
marker for endothelial function and inflammatory response 
[28].
The aim of current study was to investigate whether 
serum biomarkers reflecting myocardial remodeling, 
microfibrosis, inflammation, and vascular endotheliopathy 
are affected in the early stage of familial HCM in young 
individuals.
Methods
In total 105 participants (median age 15, range 0–30 years) 
were included in this study. Thirty-nine young individu-
als with clinical diagnosis of HCM (n = 23) and HCM-risk 
individuals (n = 16), all with heredity for familial HCM 
were recruited from 26 unrelated families with familial 
HCM from the outpatient clinics of the Pediatric and Adult 
Cardiology at the Lund University Hospital. Familial HCM 
was defined as the presence of left ventricular hypertro-
phy (Z score for intraventricular septum (IVS) and/or LV 
posterior wall (PW) thickness > 2.5 SD on echocardiogra-
phy) associated with HCM-causing mutation in the family 
or with heredity for HCM in first-degree relatives. Exclu-
sion criteria were familial HCM with outflow obstruc-
tion (HOCM), sporadic cases of HCM (i.e., cases without 
heredity for familial HCM), or LV hypertrophy (LVH) due 
to other causes, including congenital heart disease (aor-
tic stenosis, coarctation of the aorta), Noonan syndrome, 
malformation syndromes, neuromuscular and metabolic 
disorders, including diabetes, as well as smoking and 
hypertension.
The HCM-risk group consisted of offspring or siblings 
to the index patients with HCM. All risk individuals had 
normal echocardiographic examination and normal 12-lead 
electrocardiogram (ECG). The control group (n = 66) con-
sisted of healthy volunteers. A group of young individuals 
with endurance physical exercise (athlete group; n = 14, 
training >10  h/week, with left ventricular hypertrophy 
(LVH, Z score > 2 SD)) was also included, and served as 
LVH controls for HCM patients. Both controls and ath-
letes had 12-lead ECGs in normal range, and no history or 
heredity of cardiac disease.
All participants and their guardians (for those under 
18 years of age) were given verbal and written information, 
and written consent was obtained. The study was approved 




All participants underwent physical examination, 
12-lead ECG, and echocardiography. On the same occa-
sion, blood samples were taken for later analysis of serum 
biomarkers of collagen metabolism and degradation, 
extracellular matrix remodeling, systemic inflammation, 
and vascular endothelial dysfunction. A subgroup of the 
cohort also underwent cardiac magnetic resonance imaging 
(CMR). A registered research nurse collected the demo-
graphic data.
Electrocardiography
Conventional 12-lead resting ECG (Schiller AT-102, Swit-
zerland) was performed in all the participants, and analyzed 
using pooled standard ECG criteria. LV hypertrophy was 
assessed according to age-specific conventional ECG crite-
ria that have earlier been described in detail [11].
Echocardiography
Transthoracic ECG-triggered echo was performed using 
Philips’ iE33 system (Netherlands) in accordance to the 
American Society of Echocardiography’s recommenda-
tions. The echocardiographic methods have earlier been 
described in detail [11]. In summary, the LVH was defined 
as LV wall thickness in end-diastole exceeding +2 SD (in 
athletes) or +2.5 SD (in HCM group) from the mean cor-
rected for age, gender, and body surface area (BSA). The 
measurements of LV structures were expressed as Z scores 
(Z) in relation to normal distributions adjusted for age and 
BSA. For individuals older than 18 years, the normal upper 
limit for IVS or PW was set at 13 mm. LV diastolic func-
tion was assessed via pulsed Doppler of the mitral inflow 
by measuring the early filling (E) peak velocity [29]. Tissue 
doppler imaging (TDI) was performed to measure the early 
diastolic (e′) velocity [29]. E/e′ ratio was used as index of 
LV diastolic filling pressure [29]. LV mass (LVM) was cal-
culated from M-mode measurements, and indexed by divid-
ing it to height raised to exponential power of 2.7. LVM g/
m2.7 has been earlier shown to reduce the variability among 
young normal subjects, providing thus a more sensitive cut-
off for LVH [30].
Cardiac Magnetic Resonance Imaging
CMR was performed using a 1.5  T MR scanner (Philips 
Achieva, Philips Healthcare, Best, Netherlands) with a 
32-channel coil and ECG triggering. Myocardial perfusion 
(MP) was measured using flow quantification of the coro-
nary sinus during adenosine-induced hyperemia and at rest. 
The flow was divided by LVM from cine images as earlier 
described [31, 32] and validated [33]. MP was expressed in 
ml/min/g and the MP ratio (MPR) was calculated by divid-
ing MP during adenosine with MP at rest. All CMR analy-
sis was performed using the software Segment [34].
Biochemical Analysis
Blood samples were obtained from all participants in this 
study. The analyses were done on EDTA to minimize influ-
ence of proteolytic enzymes. The analysis included serum 
biomarkers of collagen metabolism and degradation, extra-
cellular matrix remodeling, as well as inflammation and 
endothelial dysfunction, by analysis of ICTP, MMP-9, 
myostatin, cathepsin S, endostatin, VEGFR1, VCAM, and 
ICAM.
Endostatin (DY1098), cathepsin S (DY1183), matrix 
metalloproteinases (MMP-9, DY911), VCAM-1 (DY809), 
and ICAM-1 (DY720) were analyzed using a commercially 
available sandwich ELISAs from R&D Systems (Minneap-
olis, MN, USA), in which a monoclonal antibody specific 
for the peptide was coated onto microtitre plates. Standards 
and samples were pipetted into the wells and the peptide 
was bound to the immobilized antibodies. After washing, 
a biotinylated antibody was added. After another incuba-
tion and washing cycle, a streptavidin-HRP conjugate was 
added. After incubation and washing, a substrate solution 
was added. The development was stopped and the absorb-
ance was measured in a SpectraMax 250 (Molecular 
Devices, Sunnyvale, CA, USA). The peptide concentra-
tions in the samples were determined by comparing the 
optical density of the sample with the standard curve. ICTP 
was measured with the UniQ EIA from Orion Diagnostica 
(Espoo, Finland). The total coefficients of variation (CV) 
for the assays were in the range of 5–7%. GDF-8/myosta-
tin was analyzed with a Quantikine ELISA from R&D Sys-
tems (DGDF80).
Information regarding the presence of the disease-caus-
ing mutation and the family history of HCM was obtained 
from medical records. All HCM genetic analyses, includ-
ing DNA sequencing and examination of the coding exons 
of the 11 most common HCM-associated genes MYH7, 
MYBPC3, MYL2, MYL3, TNNT2, TPM1, ACTC1, TNNI3, 
CSRP3, TCAP and the promoter area of PLN in the proband 
(HCM patient) were performed by Statens Serum Institut 
(SSI), Copenhagen, Denmark [35].
Statistical Analysis
Data are presented as mean +/− SEM unless otherwise 
specified. The differences between the groups were calcu-
lated using analysis of variance (ANOVA). Log transfor-
mation was used for variables with skewed (non-Gaussian) 
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distribution. When significant, Bonferroni post hoc testing 
was used to calculate the p values. A result with p < 0.05 
was considered statistically significant. Logarithmic regres-
sion analysis was used to describe the linear relationship 
between selected variables. All statistical analyses were 
performed using the statistical software Statview® 5.0 for 
Windows (SAS Institute Inc., Cary, USA).
Results
In total, 105 participants (median 15, range 0–30  years) 
were enrolled in this study as follows: 23 HCM patients, 
16 HCM-risk individuals with heredity for familial HCM, 
and 66 healthy controls, including 14 young athletes. The 
demographic characteristics of the study population are 
summarized in Table 1.
Fourteen of the 23 HCM patients (61%) were carriers of 
the previously described HCM -causing mutations as fol-
lows: Eight patients had MYBPC3 mutation, four patients 
had MYH7 mutation (one HCM patient had double muta-
tion MYBPC3 and MYH7), one patient had MYBPC3 muta-
tion and a MYBPC3 variant, one patient had TNNT2 muta-
tion, and one patient had a TCAP mutation. Twenty-one 
of the 23 HCM patients were classified as NYHA and two 
(female, age 7 and 12 years) were classified as NYHA II.
Echocardiography
The HCM group and the athletes had comparable degree 
of hypertrophy and left ventricular mass index (p > 0.1), 
whereas the Z scores for the LV PW and IVS, and LVM 
were not significantly different between the control and 
HCM-risk group (p > 0.2). The mitral septal E/e′ was 
increased in the HCM and HCM-risk groups (p < 0.05) 
compared to controls and athletes. The athletes had signifi-
cant lower E/e′ even though the degree of LVM was similar 
versus HCM (p = 0.006). The echocardiographic character-
istics of the study population are summarized in Table 2.
Biomarkers Reflecting Myocardial Remodeling, 
Coronary, and Microvascular Dysfunction
The biomarker data of the study population are sum-
marized in Table  3. Both endostatin and cathepsin S 
were increased in the HCM group compared to con-
trols (p = 0.0001 and p = 0.0009, respectively), athletes 
(p = 0.005 and p = 0.0002, respectively), and the HCM-risk 
group (p = 0.005 and p = 0.01, respectively; Fig. 1). These 
two biomarkers correlated with both left ventricular mass 
index (p ≤ 0.001, r ≥ 0.3; Fig. 2) and mitral E/e′ (p < 0.005, 
r ≥ 0.3, Fig. 3). Also, MMP-9 (Fig. 1, panel c) and VCAM 
(p = 0.04) were increased in the HCM group compared to 
controls.
In the HCM-risk group, myostatin was decreased 
(p = 0.004) and ICAM was increased (p = 0.002) as 
Table 1  The demographic 
characteristics of the study 
groups, data shown as 
mean ± SEM
Controls Athletes HCM-risk HCM
N 52 14 16 23
Age, y 17.4±0.9 17.5 ± 1.5 12.8 ± 1.6 17.5 ± 1.6
Heredity 0 0 16 14
Boys, n 26 13 9 15
Girls, n 26 1 7 8
Weight, kg 59.7 ± 2.7 68.0 ± 5.0 48.1 ± 5.2 63.3 ± 5.2
Length, cm 164.1 ± 2.4 173.5 ± 3.4 148.8 ± 6.9 162.1 ± 6.2
Body surface area 1.63 ± 0.04 1.79 ± 0.08 1.39 ± 0.1 1.67 ± 0.1
Body mass index 21.5 ± 0.6 22.1 ± 0.9 20.2 ± 0.8 22.5 ± 1.0
Blood pressure 111/68±1/1 107/71±1/1 107/67±4/1 109/67±3/1
Table 2  The echocardiographic characteristics of the study groups, 
data shown as mean ± SEM
IVS intraventricular septum in diastole (mm), PW posterior wall in 
diastole (mm), FS fractional shortening (%), EF ejection fraction (%), 
E/e′ septal ratio quotient of mitral inflow E (by pulsed Doppler), and 
septal e′ measured by tissue Doppler
LVM index represents index of left ventricular mass in relation to the 
individuals body surface area (in LVM g/m2) and in LVM g/m2.7
Controls Athletes HCM-risk HCM
IVS(mm) 8.3 ± 0.2 10.2 ± 0.5 8.2 ± 0.5 17.6 ± 1.5
IVS(SD) 1.0 ± 0.1 2.3 ± 0.3 1.6 ± 0.3 6.6 ± 0.7
PW(mm) 7.6 ± 0.2 9.1 ± 0.5 7 ± 0.4 10.3 ± 0.7
PW(SD) −0.16 ± 0.1 0.75 ± 0.5 −0.2 ± 0.4 2.4 ± 0.4
FS(%) 38 ± 0.8 36 ± 0.9 36.2 ± 1.2 44 ± 2
EF(%) 68 ± 1.0 66 ± 1.2 66 ± 1.5 75 ± 2.2
E/e′ septal 7.3 ± 0.4 6.8 ± 0.2 8.3 ± 0.4 10.2 ± 0.8
E/e′ > 8 24% 0 62% 62%
E/e′ > 12 0 0 0 25%
LVM/BSA(g/m2) 78.9 ± 2.8 95.9 ± 5.3 72.7 ± 4 130.9 ± 11.8
LVM index(g/
m2.7)
33.7 ± 0.9 38.7 ± 0.9 34.5 ± 1.9 59.8 ± 6.2
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compared to the other groups (Fig. 4). ICAM correlated 
with the myocardial perfusion during adenosine hypere-
mia, measured by CMR (Fig. 4). There was no significant 
difference in ICTP or VEGFR1 between the study groups 
(p > 0.1). However, HCM patients with E/e′ > 8 had sig-
nificantly higher ICTP than the other groups (p = 0.02).
Cardiac Magnetic Resonance
The global myocardial perfusion data are overlapping with 
the results previously reported [31]. MP was decreased 
in the HCM group versus controls (p = 0.02), even when 
using Z score > 2.5 SD for HCM diagnosis, but no signifi-
cant changes in MP were found in the HCM-risk group 
vs. controls (Fig.  5). There was an inverse relationship 
Table 3  The absolute values 
of the biochemical markers in 
the study groups, data shown as 
mean ± SEM
Controls Athletes HCM-risk HCM
Cathepsin S (pg/mL) 7927 ± 346 6711 ± 361 8031 ± 918 10,296 ± 580
Endostatin (pg/mL) 39,595 ± 1202 39,930 ± 1817 42,471 ± 2465 49,730 ± 2757
ICAM (pg/mL) 195,480 ± 8046 220,645 ± 7260 247,531 ± 14,800 178,323 ± 7538
VCAM (pg/mL) 297,296 ± 10,112 332,915 ± 20,117 313,487 ± 23,609 345,852 ± 27,780
MMP-9 (pg/mL) 119,919 ± 7719 137,246 ± 17,804 173,156 ± 25,843 218,871 ± 59,047
Myostatin (pg/mL) 3274 ± 179 3748 ± 511 2062 ± 174 3390 ± 294
VEGFRI (pg/mL) 3897 ± 2413 1892 ± 1200 1175 ± 605 603 ± 101
ICTP (ug/mL) 8.95 ± 0.7 13.9 ± 2.4 12.6 ± 1.5 12.4 ± 3
Fig. 1  a Endostatin was higher in the HCM group than in controls 
(p = 0.0001), athletes (p = 0.005), and the HCM-risk group (p = 0.03). 
Data are shown as median and interquartile range. b Cathepsin S 
was higher in the HCM group than in controls (p = 0.0009), athletes 
(p = 0.0002), and the HCM-risk group (p = 0.02). Data are shown as 
median and interquartile range. c MMP-9 was higher in the HCM 
group than in controls (p = 0.008). There was no statistically sig-
nificant difference between the HCM group and the other 2 groups 
(p = 0.1 vs. athletes, and p = 0.3 vs. the HCM-risk group). Data are 
shown as median and interquartile range.
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between serum endostatin and MP during adenosine 
hyperemia (p = 0.04, r = −0.37; Fig. 6). Myocardial perfu-
sion ratio also showed inverse relationship with LVM g/
m2.7 (p = 0.0002, r = −0.6), whereas the mitral lateral E/e′ 
(p = 0.05, r = −0.4) and septal E/e′ (p = 0.004, r = −0.5) 
measured by tissue Doppler correlated inversely to myocar-
dial perfusion change during adenosine hyperemia (Fig. 7).
Discussion
In the present study of a young cohort of HCM patients and 
HCM-risk individuals, in whom we earlier have reported 
abnormalities regarding myocardial diastolic function and 
peripheral microvascular function [11], we observed sig-
nificant changes in circulating serum biomarkers reflecting 
myocardial matrix remodeling and vascular dysfunction. 
Our findings support the hypothesis that adverse changes in 
the cardiac extracellular matrix and microcirculation result-
ing in altered myocardial tissue composition may be identi-
fied in the early phase of HCM in the young.
ECM remodeling is probably an early biological pro-
cess in the development of hypertrophic cardiomyopa-
thy, and is thought to be mediated by proteases, such as 
cathepsins and MMPs, in response to proinflammatory 
stimuli and oxidative stress. This process, along with 
altered coronary angiogenesis, which is in part mediated 
by endostatin, contributes to myocardial remodeling and 
development of fibrosis, all of which being considered 
morphological key features of HCM. Our data indicating 
elevated levels of circulating cathepsin S and endosta-
tin in the group of children and young adults with HCM 
corroborate these previous findings [11, 36–38]. In our 
study, these two biomarkers showed a clear relationship 
Fig. 2  a The relationship between endostatin and left ventricular mass index in the study groups (p = 0.001; r = 0.3). b The relationship between 
cathepsin S and left ventricular mass index in the study groups (p = 0.0001; r = 0.4).
Fig. 3  a The relationship between endostatin and the mitral septal E/e′ by tissue Doppler (p < 0.0001; r = 0.4). b The relationship between cath-
epsin S and the mitral septal E/e′ by tissue Doppler (p = 0.004; r = 0.3).
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Fig. 4  a Myostatin was lower in the HCM-risk group than in the 
other study groups (p < 0.01). Data are shown as median and inter-
quartile range. b ICAM was higher in the HCM-risk group than in 
controls (p = 0.001) and the HCM group (p = 0.0005). Data are shown 
as median and interquartile range. c The relationship between ICAM 
and the myocardial perfusion (MP) during adenosine hyperemia 
(p = 0.01; r = 0.3).
Fig. 5  Myocardial perfusion ratio was lower in the HCM group than 
in the HCM-risk group and controls (p = 0.02 for both). No differ-
ence in MPR was noted between the HCM-risk group and controls 
(p = 0.7). Data are shown as median and interquartile range.
Fig. 6  The relationship between endostatin and the myocardial per-
fusion ratio in the study groups (p = 0.046, r = − 0.4).
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to E/e´, an index of ventricular diastolic function, and to 
left ventricular mass index (LVM g/m2.7). Although we 
did not find any significant difference in circulating cath-
epsin S between controls and those at risk for HCM, the 
association of cathepsin S with these cardiac indices is in 
agreement with the results of Ho et al. [10] that showed 
increased myocardial extracellular volume using CMR in 
individuals with HCM sarcomere mutation but no myo-
cardial hypertrophy [10]. It may also explain our earlier 
finding of increased mitral E/e´ in individuals at risk for 
HCM, without noticeable cardiac hypertrophy [11].
In the present study, we observed lower levels of cir-
culating myostatin in the HCM-risk group but not in the 
HCM group. This could indicate altered myoblast stimu-
lation, a potential mechanism in the early development of 
myocardial hypertrophy. Myostatin acts through a com-
plex interaction between GH/IGF-1, intracellular SMAD 
2/3, protein kinase B (AKT) and mammalian target of 
Rapamycin (mTOR), which is capable to regulate protein 
synthesis and cell size [24]. This interaction may possibly 
explain the very rapid progress of LVH during puberty in 
HCM patients. Nevertheless, further studies are needed 
to elucidate the precise role of myostatin in the occur-
rence and progression of HCM in the young.
There are several recognized serum biomarkers for 
myocardial fibrosis such as C-terminal propeptide of type 
I procollagen (PICP), C-terminal telopeptide of type I 
(ICTP), procollagen III (PIIINP) and N-Terminal Propep-
tide (PIIINP) [13]. Due to their similarities, we selected 
only ICTP as a marker of fibrosis. In contrast to a pre-
vious report [17], we did not find significant changes 
of ICTP in our young HCM group or in the HCM-risk 
group. This could probably be explained by their young 
age and shorter duration of clinical disease. However, 
when using mitral E/e´ > 8 as a cut-off for LV diastolic 
dysfunction, we found higher levels of ICTP (p = 0.02) in 
Fig. 7  a The relationship between the myocardial perfusion ratio 
and the left ventricular mass index in the study groups (p = 0.0002, 
r= − 0.6). b The relationship between the myocardial perfusion ratio 
and the mitral lateral E/e′ in the study groups (p = 0.05, r = −0.4). c 
The relationship between the myocardial perfusion ratio and the 
mitral septal E/e´ in the study groups (p = 0.05, r = − 0.4).
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the HCM group, a finding that could suggest alterations 
in ECM prior to development of fibrosis. As recently 
reported [31], the degree of myocardial fibrosis was 
assessed using CMR -LGE, and the association between 
regional hypoperfusion and fibrosis [39] in young 
patients with HCM. In line with previous studies showing 
a certain correlation between the magnitude of fibrosis 
and the degree of hypertrophy [2, 7–9], fibrosis was pre-
dominantly found in myocardial segments with advanced 
hypertrophy [39] and also indicating a pathology beyond 
LVH and LGE by showing greater extent of areas with 
impaired myocardial perfusion even in non-fibrotic myo-
cardium during adenosine hyperemia indicating regional 
hypoxemia, suggesting an important relationship of myo-
cardial hypoperfusion with fibrosis occurrence in HCM 
[39]. Myocardial ischemia is previously suggested as an 
important complication in HCM [38] and supported by 
a previous mouse model of HCM [40] where sarcomere 
mutation-positive animals were found to upregulate genes 
involved in extracellular matrix remodeling in early stage 
of the disease, prior to the onset of histological changes 
characteristic for LVH and fibrosis. A human study [41] 
recently showed genetic variations in angiogenic and 
hypoxia-responsive genes with the association to younger 
age at diagnosis, diastolic dysfunction, and greater septal 
hypertrophy [41]. Although ICTP showed no correlation 
with any of the above CMR indices, there was an inverse 
relationship of myocardial perfusion during adenosine 
hyperemia with both LVM and mitral E/e′, a finding that 
strengthens the concept that myocardial perfusion abnor-
malities occur in parallel with the progression of myocar-
dial hypertrophy and diastolic dysfunction.
Endostatin results from the cleavage of collagen XVIII 
by proteolytic enzymes such as cathepsins and MMPs [22], 
and has important antiangiogenic properties by inhibiting 
endothelial cell proliferation and migration [20, 22, 42, 43]. 
Our findings showing inverse relationship between CMR 
myocardial perfusion and endostatin along with elevated 
circulating levels in the HCM group support the role of 
endostatin in the defective angiogenesis and possibly also 
the adenosine-induced hypoperfusion and whereby the 
regional hypoxemia found in HCM group. Higher levels 
of endostatin have also previously been shown to be asso-
ciated with left ventricular mass in a community-based 
cohort [23] which suggests that endostatin may be a marker 
of myocardial remodeling even in the absence of HCM.
A prior study suggested a link between circulating 
endostatin and endothelium-dependent vasomotor dysfunc-
tion via decrease in nitric oxide bioactivity [42]. We have 
noticed abnormal microvascular response to acetylcho-
line, an endothelium-dependent agonist, in the peripheral 
circulation in both the HCM and HCM-risk groups [11]. 
Myostatin may also exert coronary and systemic effects 
on vascular function via inhibition of eNOS phosphoryla-
tion and increase in ICAM-1 and VCAM-1 expression [44]. 
The latter could explain the elevated levels of ICAM and 
VCAM in the HCM-risk and HCM groups, respectively.
Study Limitations
HCM is a very rare disease in the young, which explains 
in part the small size of the HCM and HCM-risk cohorts. 
In addition, not all HCM probands were positive for 
known HCM mutations, but they all fulfilled the echocar-
diographic criteria for HCM and all had a family history 
for HCM. The HCM-risk group was also younger than the 
other groups. Another potential concern is biased results 
due to “common family genetics.” However, the individuals 
in the HCM and HCM-risk groups were recruited from 26 
unrelated families participating in these two groups. Intui-
tively, this would have minimized any such bias.
In conclusion, the present study indicates altered cir-
culating biomarkers of myocardial extracellular matrix 
remodeling and vascular endotheliopathy in the early phase 
of HCM in the young. The findings suggest an interesting 
pathophysiological biochemical process in early stages of 
HCM and in individuals at risk for developing this disease. 
Further studies are warranted to confirm this hypothesis 
and to assess whether they can be used to estimate the risk 
for HCM-related complications in the later phase of the 
disease. Whether these early biochemical changes reflect-
ing altered myocardial tissue composition in HCM could 
add further information in risk stratification of individuals 
with HCM-causing mutation remains to be established.
Acknowledgements We are indebted to Ms. Annika Maxedius, 
research nurse, for excellent technical assistance throughout the study.
Funding No financial assistance was received to support this study.
Compliance with Ethical Standards 
Conflict of interest There are no financial ties to products in the 
study or potential/perceived conflicts of interest.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted 
use, distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, 
Kuhn HJ, Seidman CE et  al (2003) American College of 
 Pediatr Cardiol
1 3
Cardiology/European Society of Cardiology clinical expert con-
sensus document on hypertrophic cardiomyopathy. A report of 
the American College of Cardiology Foundation task force on 
clinical expert consensus documents and the European Society 
of Cardiology Committee for Practice Guidelines. Eur Heart J 
24(21):1965–1991
 2. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cec-
chi F, Charron P, et  al. 2014 ESC guidelines on diagnosis and 
management of hypertrophic cardiomyopathy: the task force for 
the diagnosis and management of hypertrophic cardiomyopa-
thy of the European Society of Cardiology (ESC). Eur Heart J 
35(39):2733–2779.
 3. Decker JA, Rossano JW, Smith EO, Cannon B, Clunie SK, 
Gates C et al (2009) Risk factors and mode of death in isolated 
hypertrophic cardiomyopathy in children. J Am Coll Cardiol 
54(3):250–254
 4. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, 
Calkins H et al (2011) HRS/EHRA expert consensus statement 
on the state of genetic testing for the channelopathies and car-
diomyopathies: this document was developed as a partnership 
between the Heart Rhythm Society (HRS) and the European 
Heart Rhythm Association (EHRA). Europace : European pac-
ing, arrhythmias, and cardiac electrophysiology : journal of the 
working groups on cardiac pacing, arrhythmias, and cardiac cel-
lular electrophysiology of the European Society of. Cardiology 
13(8):1077–1109
 5. Marian AJ (2002) Modifier genes for hypertrophic cardiomyopa-
thy. Curr Opin Cardiol 17(3):242–252
 6. Marian AJ, Roberts R (2001) The molecular genetic basis for 
hypertrophic cardiomyopathy. J Mol Cell Cardiol 33(4):655–670
 7. Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A 
(2000) Hypertrophic cardiomyopathy and sudden death in the 
young: pathologic evidence of myocardial ischemia. Hum Pathol 
31(8):988–998
 8. Maron BJ (2002) Hypertrophic cardiomyopathy: a systematic 
review. JAMA 287(10):1308–1320
 9. Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ 
(2000) Hypertrophic cardiomyopathy: the interrelation of disar-
ray, fibrosis, and small vessel disease. Heart 84(5):476–482
 10. Ho CY, Abbasi SA, Neilan TG, Shah RV, Chen Y, Heydari B 
et  al (2013) T1 measurements identify extracellular volume 
expansion in hypertrophic cardiomyopathy sarcomere mutation 
carriers with and without left ventricular hypertrophy. Circ Car-
diovasc Imaging 6(3):415–422
 11. Fernlund E, Schlegel TT, Platonov PG, Carlson J, Carlsson M, 
Liuba P (2015) Peripheral microvascular function is altered in 
young individuals at risk for hypertrophic cardiomyopathy and 
correlates with myocardial diastolic function. Am J Physiol 
Heart Circ Physiol 308(11):H1351–H1358
 12. Gallagher GL, Jackson CJ, Hunyor SN (2007) Myocardial extra-
cellular matrix remodeling in ischemic heart failure. Front Biosci 
12:1410–1419
 13. Lijnen PJ, Maharani T, Finahari N, Prihadi JS (2012) Serum 
collagen markers and heart failure. Cardiovasc Hematol Disord 
Drug Targets 12(1):51–55
 14. Roldan V, Marin F, Gimeno JR, Ruiz-Espejo F, Gonzalez J, Feliu 
E et al (2008) Matrix metalloproteinases and tissue remodeling 
in hypertrophic cardiomyopathy. Am Heart J 156(1):85–91
 15. Noji Y, Shimizu M, Ino H, Higashikata T, Yamaguchi M, Nohara 
A et al (2004) Increased circulating matrix metalloproteinase-2 
in patients with hypertrophic cardiomyopathy with systolic dys-
function. Circ J 68(4):355–360
 16. Lombardi R, Betocchi S, Losi MA, Tocchetti CG, Aversa M, 
Miranda M et al (2003) Myocardial collagen turnover in hyper-
trophic cardiomyopathy. Circulation 108(12):1455–1460
 17. Ho CY, Lopez B, Coelho-Filho OR, Lakdawala NK, Cirino 
AL, Jarolim P et  al (2010) Myocardial fibrosis as an early 
manifestation of hypertrophic cardiomyopathy. N Engl J Med 
363(6):552–563
 18. Thurmond RL, Sun S, Karlsson L, Edwards JP (2005) Cathep-
sin S inhibitors as novel immunomodulators. Curr Opin Investig 
Drugs 6(5):473–482
 19. Shi GP, Sukhova GK, Kuzuya M, Ye Q, Du J, Zhang Y et al 
(2003) Deficiency of the cysteine protease cathepsin S impairs 
microvessel growth. Circ Res 92(5):493–500
 20. Mitsuma W, Kodama M, Hanawa H, Ito M, Ramadan MM, 
Hirono S et al (2007) Serum endostatin in the coronary circu-
lation of patients with coronary heart disease and its relation to 
coronary collateral formation. Am J Cardiol 99(4):494–498
 21. Akerfeldt T, Gunningberg L, Swenne CL, Ronquist G, Larsson 
A (2014) Elective orthopedic and cardiopulmonary bypass sur-
gery causes a reduction in serum endostatin levels. Eur J Med 
Res 19(1):61
 22. Wickstrom SA, Veikkola T, Rehn M, Pihlajaniemi T, Alitalo 
K, Keski-Oja J (2001) Endostatin-induced modulation of plas-
minogen activation with concomitant loss of focal adhesions 
and actin stress fibers in cultured human endothelial cells. 
Cancer Res 61(17):6511–6516
 23. Carlsson AC, Ruge T, Sundstrom J, Ingelsson E, Larsson A, 
Lind L et  al (2013) Association between circulating endosta-
tin, hypertension duration, and hypertensive target-organ dam-
age. Hypertension 62(6):1146–1151
 24. Breitbart A, Auger-Messier M, Molkentin JD, Heineke J 
(2011) Myostatin from the heart: local and systemic actions in 
cardiac failure and muscle wasting. Am J Physiol Heart Circ 
Physiol 300(6):H1973–H1982
 25. Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel 
T, Komen W et  al (2004) Myostatin mutation associated 
with gross muscle hypertrophy in a child. N Engl J Med 
350(26):2682–2688
 26. George I, Bish LT, Kamalakkannan G, Petrilli CM, Oz MC, 
Naka Y et  al (2010) Myostatin activation in patients with 
advanced heart failure and after mechanical unloading. Eur J 
Heart Fail 12(5):444–453
 27. Haverslag R, Pasterkamp G, Hoefer IE (2008) Targeting adhe-
sion molecules in cardiovascular disorders. Cardiovasc Hematol 
Disord Drug Targets 8(4):252–260
 28. Shibuya M (2006) Differential roles of vascular endothelial 
growth factor receptor-1 and receptor-2 in angiogenesis. J Bio-
chem Mol Biol 39(5):469–478
 29. Gaulito L, Badano L, Fox K, Sicari R, Zamorano JL. (2011)The 
EAE textbook of echocardiography, Oxford, Oxford University 
Press
 30. Khoury PR, Mitsnefes M, Daniels SR, Kimball TR (2009) Age-
specific reference intervals for indexed left ventricular mass in 
children. J Am Soc Echocardiogr 22(6):709–714
 31. Gyllenhammar T, Fernlund E, Jablonowski R, Jogi J, Engblom 
H, Liuba P et al (2014) Young patients with hypertrophic cardio-
myopathy, but not subjects at risk, show decreased myocardial 
perfusion reserve quantified with CMR. Eur Heart J Cardiovasc 
Imaging 15(12):1350–1357
 32. Carlsson M, Jogi J, Bloch KM, Heden B, Ekelund U, Stahlberg 
F et  al (2015) Submaximal adenosine-induced coronary hyper-
aemia with 12  h caffeine abstinence: implications for clinical 
adenosine perfusion imaging tests. Clin Physiol Funct Imaging 
35(1):49–56
 33. Bloch KM, Carlsson M, Arheden H, Stahlberg F (2009) Quanti-
fying coronary sinus flow and global LV perfusion at 3 T. BMC 
Med Imaging 9:9
 34. Heiberg E, Sjogren J, Ugander M, Carlsson M, Engblom H, 
Arheden H (2010) Design and validation of segment–freely 
Pediatr Cardiol 
1 3
available software for cardiovascular image analysis. BMC Med 
Imaging 10:1
 35. Havndrup O, Bundgaard H, Andersen PS, Allan Larsen L, Vuust 
J, Kjeldsen K, Christiansen M (2003) Outcome of clinical versus 
genetic family screening in hypertrophic cardiomyopathy with 
focus on cardiac beta-myosin gene mutations. Cardiovasc Res 
57(2):347–357
 36. Heffernan KS, Napolitano CA, Maron MS, Patvardhan EA, Patel 
AR, Pandian NG et  al (2010) Peripheral vascular endothelial 
function in patients with hypertrophic cardiomyopathy. Am J 
Cardiol 105(1):112–115
 37. Cambronero F, Marin F, Roldan V, Hernandez-Romero D, 
Valdes M, Lip GY (2009) Biomarkers of pathophysiology in 
hypertrophic cardiomyopathy: implications for clinical manage-
ment and prognosis. Eur Heart J 30(2):139–151
 38. Dimitrow PP, Undas A, Bober M, Tracz W, Dubiel JS (2007) 
Plasma biomarkers of endothelial dysfunction in patients with 
hypertrophic cardiomyopathy. Pharmacol Rep 59(6):715–720
 39. Jablonowski R, Fernlund E, Aletras A, Engblom H, Heiberg E, 
Liuba P, et  al. Regional stress-induced ischemia in non-fibrotic 
hypertrophied myocardium demonstrated on cardiovascular 
magnetic resonance imaging in young HCM patients. Pediatr 
Cardiol 2015: 2015; 36(8): 1662–9
 40. Kim JB, Porreca GJ, Song L, Greenway SC, Gorham JM, Church 
GM et  al (2007) Polony multiplex analysis of gene expression 
(PMAGE) in mouse hypertrophic cardiomyopathy. Science 
316(5830):1481–1484
 41. Alkon J, Friedberg MK, Manlhiot C, Manickaraj AK, Kinnear 
C, McCrindle BW et  al (2012) Genetic variations in hypoxia 
response genes influence hypertrophic cardiomyopathy pheno-
type. Pediatr Res 72(6):583–592
 42. Jin S, Zhang Y, Yi F, Li PL (2008) Critical role of lipid raft redox 
signaling platforms in endostatin-induced coronary endothelial 
dysfunction. Arterioscler Thromb Vasc Biol 28(3):485–490
 43. Folkman J (2006) Antiangiogenesis in cancer therapy–endostatin 
and its mechanisms of action. Exp Cell Res 312(5):594–607
 44. Guo W, Wong S, Bhasin S (2013) AAV-mediated administration 
of myostatin pro-peptide mutant in adult Ldlr null mice reduces 
diet-induced hepatosteatosis and arteriosclerosis. PloS ONE 
8(8):e71017
